Pyrotinib in Women With High-risk in Early Stage Breast Cancer

Inclusion Criteria

• •1. Subjects voluntarily participate in this study and sign the informed consent form；
• •2. Female or male patients, aged ≥ 18 years, and ≤75 years;
• •3. ECOG PS score: 0-1;
• •4. Patients with HER2+ early or locally advanced breast cancer confirmed by histopathology: HER2-positive is defined by standard of 3+ by immunohistochemical staining (IHC), or 2+ by immunohistochemical staining (IHC) but positive by in situ hybridization (ISH).
• •5. Stage II through IIIC HER-2 positive breast cancer with node positive disease after surgery.
• •6. Been treated for early breast cancer with standard of care duration of trastuzumab combined with pertuzumab or T-DM1.
• •7. Could have been treated neoadjuvantly but have not reached pathologic complete response.